Tempest Therapeutics Inc (TPST)

10:35 AM

Tempest Therapeutics stock rises on EMA Orphan Drug Designation - Investing.com

10:35 AM

08:53 AM

Tempest Therapeutics Says Amezalpat Gets EMA Orphan Drug Designation in Liver Cancer - marketscreener.com

08:53 AM

08:46 AM

Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat - Nasdaq

08:46 AM

08:16 AM

TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News - GuruFocus

08:16 AM

08:04 AM

Tempest Receives Orphan Drug Designation from the European - GlobeNewswire

08:04 AM

May 23, 2025

Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 23, 2025

May 19, 2025

HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World

May 19, 2025

May 16, 2025

Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 16, 2025

Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace

May 16, 2025

May 14, 2025

TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus

May 14, 2025

May 13, 2025

Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com

May 13, 2025

May 13, 2025

Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq

May 13, 2025

May 13, 2025

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 13, 2025

May 13, 2025

FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan

May 13, 2025

May 11, 2025

Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com

May 11, 2025

May 08, 2025

Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN

May 08, 2025

May 05, 2025

Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView

May 05, 2025

May 04, 2025

Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

May 04, 2025

Apr 30, 2025

XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World

Apr 30, 2025

Apr 29, 2025

Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada

Apr 29, 2025

Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times

Apr 28, 2025

Apr 28, 2025

Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq

Apr 28, 2025

Apr 28, 2025

Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire

Apr 28, 2025

Apr 28, 2025

Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan

Apr 28, 2025

Apr 28, 2025

Tempest Therapeutics regains Nasdaq compliance - Investing.com

Apr 28, 2025

Apr 27, 2025

Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX

Apr 27, 2025

Apr 24, 2025

Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE

Apr 24, 2025

Apr 22, 2025

Tempest Therapeutics - The Pharma Letter

Apr 22, 2025

Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria

Apr 21, 2025

Apr 21, 2025

Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia

Apr 21, 2025

Apr 21, 2025

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times

Apr 21, 2025

Apr 21, 2025

FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan

Apr 21, 2025

Apr 19, 2025

Tempest to explore alternatives to advance promising pipeline - The Pharma Letter

Apr 19, 2025

Apr 13, 2025

TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN

Apr 13, 2025

Apr 12, 2025

Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025

Apr 12, 2025

HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World

Apr 12, 2025

Apr 11, 2025

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable

Apr 11, 2025

Apr 10, 2025

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga

Apr 10, 2025

Apr 10, 2025

Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive

Apr 10, 2025

Apr 10, 2025

HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com

Apr 10, 2025

Apr 10, 2025

Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance

Apr 10, 2025

Apr 10, 2025

Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News

Apr 10, 2025

Apr 09, 2025

Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks

Apr 09, 2025

Apr 09, 2025

Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com

Apr 09, 2025

Apr 09, 2025

Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com

Apr 09, 2025